Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cash from Financing Activities: 2014-2025

Historic Cash from Financing Activities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 11 years, with Sep 2025 value amounting to $10.9 million.

  • Viridian Therapeutics, Inc.\DE's Cash from Financing Activities fell 95.57% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.4 million, marking a year-over-year decrease of 90.93%. This contributed to the annual value of $457.7 million for FY2024, which is 102.83% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Cash from Financing Activities of $10.9 million as of Q3 2025, which was up 1,321.07% from $764,000 recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's Cash from Financing Activities' 5-year high stood at $290.9 million during Q3 2022, with a 5-year trough of $108,000 in Q2 2024.
  • Moreover, its 3-year median value for Cash from Financing Activities was $10.9 million (2025), whereas its average is $64.0 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first crashed by 99.78% in 2021, then soared by 15,202.35% in 2022.
  • Quarterly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Cash from Financing Activities stood at $170,000 in 2021, then spiked by 15,202.35% to $26.0 million in 2022, then spiked by 664.75% to $198.9 million in 2023, then crashed by 82.14% to $35.5 million in 2024, then tumbled by 95.57% to $10.9 million in 2025.
  • Its Cash from Financing Activities stands at $10.9 million for Q3 2025, versus $764,000 for Q2 2025 and $9.2 million for Q1 2025.